Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways

Lynne V. Abruzzo, Carmen D. Herling, George A. Calin, Christopher Oakes, Lynn L. Barron, Haley E. Banks, Vikram Katju, Michael J. Keating, Kevin R. Coombes

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Although trisomy 12 (+12) chronic lymphocytic leukemia (CLL) comprises about 20% of cases, relatively little is known about its pathophysiology. These cases often demonstrate atypical morphological and immunophenotypic features, high proliferative rates, unmutated immunoglobulin heavy chain variable region genes, and a high frequency of NOTCH1 mutation. Patients with +12 CLL have an intermediate prognosis, and show higher incidences of thrombocytopenia, Richter transformation, and other secondary cancers. Despite these important differences, relatively few transcriptional profiling studies have focused on identifying dysregulated pathways that characterize +12 CLL, and most have used a hierarchical cytogenetic classification in which cases with more than one recurrent abnormality are categorized according to the abnormality with the poorest prognosis. In this study, we sought to identify protein-coding genes whose expression contributes to the unique pathophysiology of +12 CLL. To exclude the likely confounding effects of multiple cytogenetic abnormalities on gene expression, our +12 patient cohort had +12 as the sole abnormality. We profiled samples obtained from 147 treatment-naïve patients. We compared cases with +12 as the only cytogenetic abnormality to cases with only del(13q), del(11q), or diploid cytogenetics using independent discovery (n=97) and validation (n=50) sets. We demonstrate that CLL cases with +12 as the sole abnormality express a unique set of activated pathways compared to other cytogenetic subtypes. Among these pathways, we identify the NFAT signaling pathway and the immune checkpoint molecule, NT5E (CD73), which may represent new therapeutic targets.

Original languageEnglish (US)
Pages (from-to)2069-2078
Number of pages10
JournalHaematologica
Volume103
Issue number12
DOIs
StatePublished - Nov 30 2018
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways'. Together they form a unique fingerprint.

Cite this